The role of eNOS, iNOS and NFκB in upregulation and activation of ...

Ye Y, et al. Mechanisms of COX2 upregulation by atorvastatin 22
and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010,
2000.
29. Liu SF, Ye X and Malik AB. Inhibition of NF-kappaB activation by pyrrolidine
dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100:
1330-1337, 1999.
30. Meng W, Ayata C, Waeber C, Huang PL and Moskowitz MA. Neuronal NOScGMP-dependent
ACh-induced relaxation in pial arterioles of endothelial NOS knockout
mice. Am J Physiol 274: H411-415, 1998.
31. Mensah K, Mocanu MM and Yellon DM. Failure to protect the myocardium
against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by
acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted
on chromosome ten? J Am Coll Cardiol 45: 1287-1291, 2005.
32. Planavila A, Laguna JC and Vazquez-Carrera M. Atorvastatin improves
peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing
nuclear factor-kappa B activation. Biochim Biophys Acta 1687: 76-83, 2005.
33. Planavila A, Sanchez RM, Merlos M, Laguna JC and Vazquez-Carrera M.
Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1
(PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochim Biophys
Acta 1736: 120-127, 2005.
34. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF
and Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with
combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20: 27-36, 2006.
35. Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki
Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S,
Hori M and Kitakaze M. Optimal windows of statin use for immediate infarct
limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3kinase.
Circulation 110: 2143-2149, 2004.
36. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, 3rd, Trocha SD,
Huang PL, Smith MB, Lefer AM and Lefer DJ. Simvastatin exerts both antiinflammatory
and cardioprotective effects in apolipoprotein E-deficient mice. Circulation
103: 2598-2603, 2001.
37. Sharp BR, Jones SP, Rimmer DM and Lefer DJ. Differential response to
myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol
282: H2422-2426, 2002.
38. Shinmura K, Nagai M, Tamaki K, Tani M and Bolli R. COX-2-derived
prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts.
Am J Physiol Heart Circ Physiol 283: H2534-2543, 2002.
39. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A and
Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of
ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 97: 10197-
10202, 2000.
40. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y and Bolli R.
Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of
conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602-
608, 2002.
Copyright Information
Page 22 of 35